Hillevax Inc

NASDAQ HLVX

Download Data

Hillevax Inc Short-Term Debt to Total Assets Ratio 5 year CAGR for the year ending December 31, 2023

Hillevax Inc Short-Term Debt to Total Assets Ratio 5 year CAGR is NA for the year ending December 31, 2023. The short-term debt to total assets ratio measures the proportion of short-term debt to total assets of a company. It is calculated by dividing the short-term debt by the total assets. This ratio indicates the extent to which short-term debt contributes to the company's total asset structure. A higher ratio suggests a higher level of short-term debt relative to total assets. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
  • Hillevax Inc Short-Term Debt to Total Assets Ratio for the year ending December 31, 2022 was 0.00, a -99.99% change year over year.
  • Hillevax Inc Short-Term Debt to Total Assets Ratio for the year ending December 31, 2021 was 1.24, a -79.21% change year over year.
  • Hillevax Inc Short-Term Debt to Total Assets Ratio for the year ending December 31, 2020 was 5.99.
NASDAQ: HLVX

Hillevax Inc

CEO Dr. Robert M. Hershberg M.D., Ph.D.
IPO Date April 29, 2022
Location United States
Headquarters 75 State Street, Boston, MA, United States, 02109
Employees 90
Sector Healthcare
Industry Biotechnology
Description

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.

Similar companies

ELYM

Eliem Therapeutics Inc

NA

NA

MNOV

MediciNova Inc

NA

NA

GLUE

Monte Rosa Therapeutics Inc

NA

NA

VIGL

Vigil Neuroscience Inc

NA

NA

IPSC

Century Therapeutics Inc

NA

NA

EWTX

Edgewise Therapeutics Inc

NA

NA

CGEM

Cullinan Oncology LLC

NA

NA

CNTA

Centessa Pharmaceuticals PLC ADR

NA

NA

STRO

Sutro Biopharma

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email